Tebentafusp provides overall survival benefit compared to nivolumab plus ipilimumab in first-line metastatic uveal melanoma

According to a recent study, a propensity score analysis indicated an overall survival benefit for tebentafusp compared to nivolumab plus ipilimumab (N+I) in patients with untreated metastatic uveal melanoma (mUM). This study’s findings were published in the journal, Annals of oncology.

In this study, the overall survival (OS) of patients with untreated mUM were compared between those treated with tebentafusp or pembrolizumab (IMCgp100-202) and those treated with N+I (GEM1402) using propensity scoring methods. The analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, baseline lactate dehydrogenase (LDH), sex, baseline alkaline phosphatase, Eastern Cooperative Oncology Group status, disease location, and time from primary diagnosis to metastasis. The OS was evaluated using Cox proportional hazard models and IPT-weighted Kaplan-Meier.

In the primary IPTW analysis, a total of 240 patients out of 252 who were assigned to receive tebentafusp from IMCgp100-202 were included, and 45 out of the 52 patients who underwent N+I treatment from GEM-1402 were also considered. After adjusting for IPTW, tebentafusp showed a favorable OS, with a hazard ratio (HR) of 0.52. The one-year OS for tebentafusp was 73%, while it was 50% for the N+I group. Sensitivity analyses consistently demonstrated a superior OS for tebentafusp, with all IPTW HRs ≤0.61.

Based on the above results, a propensity score analysis determined that tebentafusp provided  a similar  OS benefit compared to N+I in patients with untreated mUM.